GoodRx (NASDAQ:GDRX) and Mercurity Fintech (NASDAQ:MFH) Head-To-Head Comparison

Mercurity Fintech (NASDAQ:MFHGet Free Report) and GoodRx (NASDAQ:GDRXGet Free Report) are both business services companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, valuation, earnings, institutional ownership, risk, analyst recommendations and profitability.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Mercurity Fintech and GoodRx, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Mercurity Fintech 0 0 0 0 N/A
GoodRx 1 8 10 0 2.47

GoodRx has a consensus price target of $8.78, suggesting a potential upside of 31.21%. Given GoodRx’s higher probable upside, analysts plainly believe GoodRx is more favorable than Mercurity Fintech.

Institutional & Insider Ownership

30.8% of Mercurity Fintech shares are held by institutional investors. Comparatively, 63.8% of GoodRx shares are held by institutional investors. 62.8% of Mercurity Fintech shares are held by company insiders. Comparatively, 1.4% of GoodRx shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.


This table compares Mercurity Fintech and GoodRx’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Mercurity Fintech N/A N/A N/A
GoodRx -1.18% 2.45% 1.25%

Valuation & Earnings

This table compares Mercurity Fintech and GoodRx’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Mercurity Fintech $326,591.00 189.42 -$5.64 million N/A N/A
GoodRx $750.27 million 3.52 -$8.87 million ($0.02) -334.33

Mercurity Fintech has higher earnings, but lower revenue than GoodRx.

Volatility & Risk

Mercurity Fintech has a beta of 2.02, meaning that its share price is 102% more volatile than the S&P 500. Comparatively, GoodRx has a beta of 1.42, meaning that its share price is 42% more volatile than the S&P 500.


GoodRx beats Mercurity Fintech on 6 of the 11 factors compared between the two stocks.

About Mercurity Fintech

(Get Free Report)

Mercurity Fintech Holding Inc. operates as a fintech company powered by blockchain. The company provides digital asset trading infrastructure solutions based on internet and blockchain technologies for cryptocurrency traders; and asset digitalization platform, which offers blockchain-based digitalization solutions for traditional assets, such as fiat currencies, bonds, and precious metals. It also offers cryptocurrency mining services that provides computing power to the mining pool; and digital consultation services, such as digital payment solutions, asset management, and online and traditional brokerage services. The company was formerly known as JMU Limited and changed its name to Mercurity Fintech Holding Inc. in April 2020. Mercurity Fintech Holding Inc. was incorporated in 2011 and is headquartered in New York, New York.

About GoodRx

(Get Free Report)

GoodRx Holdings, Inc., together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices. It also offers other healthcare products and services, including subscriptions, and pharma manufacturer solutions, as well as telehealth services through the GoodRx Care platform. It serves pharmacy benefit managers who manage formularies and prescription transactions, including establishing pricing between consumers and pharmacies. The company was founded in 2011 and is headquartered in Santa Monica, California.

Receive News & Ratings for Mercurity Fintech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mercurity Fintech and related companies with's FREE daily email newsletter.